Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ketamine has rapid anxiolytic effects in treatment-resistant obsessive compulsive, post-traumatic stress, generalised anxiety and social anxiety disorders. OBJECTIVES: This study aimed to assess changes following acute and maintenance ketamine therapy on the Fear Questionnaire (FQ) subscales and the Spielberger State Anxiety Inventory (SSAI). METHODS: This secondary analysis used data from a mixed open-label and double-blinded placebo-controlled study. A total of 24 patients received short-term ascending subcutaneous doses of ketamine and were then eligible to enter a 3-month maintenance phase of 1 mg/kg ketamine dosed once or twice weekly. FQ and SSAI data were analysed using mixed models to identify between-dose differences and to describe trends during maintenance. RESULTS: Acute ketamine dosing showed a rapid dose-related reduction in all three FQ subscales (agoraphobia, social phobia and blood-injury phobia) and in the SSAI. A progressive decrease in pre-dose rating-scale scores was evident during the 3 months of maintenance therapy. CONCLUSIONS: Ketamine demonstrated dose-related improvements in all FQ subscales and in the SSAI. Both scales appear to be suitable tools to assess the anxiolytic effects of ketamine in patients with treatment-resistant anxiety. Furthermore, ketamine appears to have broad, dose-related anti-phobic effects. These findings raise the possibility that ketamine may have therapeutic potential in the treatment of other phobic states, such as specific phobia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
State-Trait Anxiety Inventory for Adults
Spielberger, C. D. (2012) · PsycTESTS Dataset · doi:10.1037/t06496-000 · Cited by 3,479
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Brief standard self-rating for phobic patients
Marks, I. M., & Mathews, A. M. (1979) · Behaviour Research and Therapy · doi:10.1016/0005-7967(79)90041-x · Cited by 1,801 · cited 4×
“The psychometric properties of the FQ have been assessed, with adequate retest reliability scores (Marks and Mathews, 1979; Mavissakalian and Michelson, 1983), internal validity (Cox et al., 1993; Moylan and Oei, 1992), discriminant validity and support for a threefactor structure associated with…”
MethodInfluentialJulian, L. J. (2011) · Arthritis Care & Research · doi:10.1002/acr.20561 · Cited by 1,794
Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613
Collaborators, W. W. M. H. S., Stein, D. J., Lim, C. C. W., Roest, A. M., de Jonge, P., Aguilar-Gaxiola, S., Al-Hamzawi, A., Alonso, J., Benjet, C., Bromet, E. J., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0889-2 · Cited by 520
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
Treatment-resistant anxiety disorders
Bystritsky, A. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001852 · Cited by 289 · cited 1×
“Co-morbidity is extremely common in patients with refractory anxiety disorders (Bystritsky, 2006; Stein et al., 2017), and we believe our cohort represents a real-world population In addition, our cohort had significant anxiety severity, ranking in the 90th percentile for FQ-SP and FQ-Ag and in the…”
BackgroundGillis, M. M., Haaga, D. A. F., & Ford, G. T. (1995) · Psychological Assessment · doi:10.1037/1040-3590.7.4.450 · Cited by 236 · cited 2×
“, 2017), and we believe our cohort represents a real-world population In addition, our cohort had significant anxiety severity, ranking in the 90th percentile for FQ-SP and FQ-Ag and in the 60th percentile for FQ-BI (Gillis et al., 1995).”
Background
Cited by
Ketamine treatment for refractory anxiety: A systematic review
Tully, J. L., Dahlén, A. D., Haggarty, C. J., Schiöth, H. B., & Brooks, S. J. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15374 · Cited by 103
“A recent open-label, double-blind, psychoactive-controlled study by Truppman Lattie et al evaluated patients (n = 24) with refractory anxiety who received acute and maintenance ketamine therapy (the same cohort described in the studies above).(37) Ascending subcutaneous ketamine (0.”
BackgroundWhittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211056743 · Cited by 56
Self-citationThe role of mGluR5 on the therapeutic effects of ketamine in Wistar rats
Gokalp, D., & Ünal, G. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06571-3 · Cited by 16
“It has also demonstrated potential in alleviating symptoms of anxiety (Silote et al. 2020; Truppman Lattie et al. 2021) and in the modulation of fear memory (Choi et al. 2020; Silote et al. 2020).”
BackgroundBertolini, F., Robertson, L., Bisson, J. I., Meader, N., Churchill, R. C., Ostuzzi, G., Stein, D. J., Williams, T., & Barbui, C. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013613.pub2 · Cited by 13
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Metadata
- Authors
- Truppman Lattie, D., Nehoff, H., Neehoff, S., Gray, A., & Glue, P.
- Affiliations
- Department of Psychological Medicine, University of Otago, Dunedin, New Zealand
- University of Otago (NZ)
- Corresponding author
- Glue, Paul
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-09-09
- Volume
- 35
- Issue
- 2
- Pages
- 137-141
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W3084122565
- Cited by
- 13
- References
- 19
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 2 · 2022: 1 · 2021: 2
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- brain health institute, rutgers university
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- ketamine, anxiolytic effects, treatment-resistant anxiety, Fear Questionnaire, phobia, agoraphobia, social anxiety disorder, specific phobia, dose-response relationship
- MeSH terms
- Phobia, Social, Anxiety, Anxiety Disorders, Double-Blind Method, Fear, Female, Humans, Ketamine, Male, Phobic Disorders, Psychometrics, Surveys and Questionnaires, Anti-Anxiety Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. https://app.cochat.ai/papers/10.1177/0269881120953991
- The paper
- Truppman Lattie, D., Nehoff, H., Neehoff, S., Gray, A., & Glue, P. (2021). Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. Journal of Psychopharmacology. https://doi.org/10.1177/0269881120953991
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.